Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
about
Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.
P2860
Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@ast
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@en
type
label
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@ast
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@en
prefLabel
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@ast
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@en
P2093
P2860
P356
P1476
Low-molecular-weight heparin v ...... rvention: a combined analysis.
@en
P2093
Anissa Bouzamondo
Jean-Sébastien Hulot
Maria Borentain
Philippe Lechat
P2860
P304
P356
10.1002/CCD.20352
P577
2005-06-01T00:00:00Z